DY
DY
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
1
$551K
Insider Sales
0
$0
Total Volume
$551K
7 transactions
Net Activity
+$551K
Net buying
Sentiment Rating
Moderate AccumulationCEO Conviction Index
No Recent Signal
Key Drivers
- •Strong buying bias: purchases represent 100% of total transaction value.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
3 Insiders
$64.43M total
Quick Actions
DY has an insider buy conviction of 100%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at DY (DY) engaged in a total of 7 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 0 were sales. The total volume of insider trading reached $551K.
The net insider activity for DY shows a net buying bias of $551K. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 71.3K shares valued at $60.64M on Sep 9, 2026.
Anthropic retail traders face losses as shares dive 13% the day after debut
Tech stock sell-off drags markets down as Anthropic shares slide
Anthropic stock teeters close to IPO price in second day of trading
Morgan Stanley Ends Anthropic Stock Support After Just One Day
SoftBank suffers worst day in over two years as AI sell-off hits Asian tech stocks
Anthropic stock closes 17% higher on its first trading day as Nasdaq sputters
Related News & Analyst Reports
Read original insights and educational research covering DY and the Unknown sector.
The Biotech Executive Playbook: Tracking Clinical Phase SEC Filings
An empirical study on how clinical-stage biotech executives execute Form 4 open-market purchases ahead of trial data releases, outlining the regulatory gaps and alpha potential of clinical insider tracking.
a16z Capital Distributions vs. Open-Market Insider Buying: A 2026 Study
A 2026 empirical study comparing Andreessen Horowitz's in-kind share distributions to LPs against open-market insider purchases, revealing which signal better predicts 12-month price performance.
Insider Trading and Earnings Announcements: Spotting the Catalyst
How does insider trading activity in the 30 days before earnings compare to post-announcement prices? This study quantifies the predictive power of pre-earnings Form 4 purchases after accounting for blackout period compliance.
Venture Spinoffs vs. Direct Listings: A Comparative Analysis of Insider Holding Trends
Venture-backed spinoffs and direct listings both skip traditional IPO underwriting, but their insider holding dynamics differ sharply. This study compares Form 4 patterns at spinoff-versus-direct-listing companies to identify which structure produces stronger alignment signals.
Tracking Insiders in Dow Jones Companies: A 10-Year Study
A decade-long empirical study of Form 4 insider buying activity across all 30 Dow Jones Industrial Average components, analyzing purchase frequency, transaction size, CEO versus director patterns, and 12-month forward performance across different market regimes.
How the Stock Market Reacts to Sudden CEO Resignations and Insider Sells
When a CEO abruptly resigns with a cluster of insider sells immediately following, the market often misses the full picture. This event study tracks 90-day price reactions to sudden leadership changes paired with Form 4 selling activity.
FAQs About DY Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for DY.